INCY
Incyte Corporation
Price Chart
Latest Quote
$108.43
-0.03 (-0.03%)
Current Price
| Previous Close | $108.46 |
| Open | $108.35 |
| Day High | $110.75 |
| Day Low | $106.48 |
| Volume | 534,664 |
Stock Information
| Shares Outstanding | 199.78M |
| Total Debt | $39.43M |
| Cash Equivalents | $4.02B |
| Revenue | $5.36B |
| Net Income | $1.43B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $21.66B |
| P/E Ratio | 15.31 |
| EPS (TTM) | $7.08 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $17.70B |
| Sales | $5.36B |
| Income | $1.43B |
| Book/sh | $28.12 |
| Cash/sh | $20.10 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 3.40 |
| Current Ratio | 3.68 |
| Debt/Eq | 0.70 |
| EPS Growth TTM | 91.70% |
Returns & Margins
| ROA | 13.89% |
| ROE | 30.82% |
| Gross Margin | 52.77% |
| Operating Margin | 25.55% |
| Profit Margin | 26.71% |
Ownership
| Insider Ownership | 1.88% |
| Institutional Ownership | 106.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.79 |
| PEG | 0.36 |
| P/S | 4.04 |
| P/B | 3.86 |
Analyst Data
| Recommendation | buy |
| Target Price | $110.26 |
Technical Indicators
| SMA20 | $101.66 |
| SMA50 | $98.94 |
| SMA200 | $97.20 |
| RSI | 61.47 |
| ATR | 4.6432 |
| Shares Float | 167.52M |
| Short Float | 9.83% |
| Short Ratio | 8.37 |
| Volatility | 0.79 |
| Rel Volume | 0.25 |
Performance History
| Week | +9.54% |
| Month | +11.67% |
| Quarter | +17.56% |
| 6 Months | +7.67% |
| YTD | +6.91% |
| Year | +57.12% |
| 3 Years | +75.60% |
| 5 Years | +30.43% |
| 10 Years | +49.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $108.43 | 534,662 |
| 2026-06-24 | $108.46 | 1,963,400 |
| 2026-06-23 | $104.40 | 1,671,000 |
| 2026-06-22 | $103.66 | 2,204,900 |
| 2026-06-18 | $98.22 | 4,058,600 |
| 2026-06-17 | $98.99 | 1,716,100 |
| 2026-06-16 | $99.75 | 1,556,100 |
| 2026-06-15 | $101.98 | 2,815,000 |
| 2026-06-12 | $108.53 | 1,488,900 |
| 2026-06-11 | $107.83 | 2,318,300 |
| 2026-06-10 | $105.39 | 2,654,400 |
| 2026-06-09 | $103.23 | 2,318,800 |
| 2026-06-08 | $100.64 | 2,975,200 |
| 2026-06-05 | $102.38 | 2,641,100 |
| 2026-06-04 | $101.24 | 1,780,000 |
| 2026-06-03 | $97.98 | 2,269,900 |
| 2026-06-02 | $92.24 | 2,021,800 |
| 2026-06-01 | $95.59 | 1,592,400 |
| 2026-05-29 | $96.74 | 2,903,000 |
| 2026-05-28 | $97.50 | 1,305,300 |
| 2026-05-27 | $97.34 | 939,600 |
| 2026-05-26 | $97.10 | 1,176,000 |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
đ° Latest News
2 Growth Stocks to Add to Your Roster and 1 We Avoid
StockStory âĸ 2026-06-22T13:31:19Z
Here Are Mondayâs Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More
24/7 Wall St. âĸ 2026-06-22T12:02:21Z
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
Barchart âĸ 2026-06-22T09:33:03Z
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Zacks âĸ 2026-06-17T10:47:00Z
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Zacks âĸ 2026-06-15T14:43:00Z
Verizon Upgraded, Oracle Downgraded: Updated Rankings on Top Blue-Chip Stocks
InvestorPlace âĸ 2026-06-15T13:51:28Z
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity
Simply Wall St. âĸ 2026-06-12T03:12:25Z
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
Exec Edge âĸ 2026-06-11T19:56:49Z
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
Investor's Business Daily âĸ 2026-06-11T17:48:06Z
Why Incyte (INCY) Stock Is Up Today
StockStory âĸ 2026-06-10T20:33:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $372,100,000 | $312,100,000 | $254,990,000 | $207,000,000 |
| Cost Of Revenue | $372,100,000 | $312,100,000 | $254,990,000 | $207,000,000 |
| Total Revenue | $5,141,242,000 | $4,241,217,000 | $3,695,649,000 | $3,394,635,000 |
| Operating Revenue | $5,141,242,000 | $4,241,217,000 | $3,695,649,000 | $3,394,635,000 |
| Expenses | ||||
| Interest Expense | $2,428,000 | $2,280,000 | $2,551,000 | $2,666,000 |
| Total Expenses | $3,798,452,000 | $4,139,923,000 | $3,040,291,000 | $2,803,009,000 |
| Other Income Expense | $218,525,000 | $88,831,000 | $22,994,000 | $-100,258,000 |
| Other Non Operating Income Expenses | $25,110,000 | $12,809,000 | $13,934,000 | $-519,000 |
| Net Non Operating Interest Income Expense | $103,172,000 | $126,430,000 | $155,863,000 | $37,785,000 |
| Interest Expense Non Operating | $2,428,000 | $2,280,000 | $2,551,000 | $2,666,000 |
| Operating Expense | $3,426,352,000 | $3,827,823,000 | $2,785,301,000 | $2,596,009,000 |
| General And Administrative Expense | $1,376,200,000 | $1,222,000,000 | $1,161,300,000 | $1,002,100,000 |
| Other Operating Expenses | - | $-1,025,000 | $2,045,000 | $7,973,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Net Interest Income | $103,172,000 | $126,430,000 | $155,863,000 | $37,785,000 |
| Interest Income | $105,600,000 | $128,710,000 | $158,414,000 | $40,451,000 |
| Normalized Income | $1,137,140,205 | $-27,442,380 | $591,108,770 | $404,891,916 |
| Net Income From Continuing And Discontinued Operation | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Total Operating Income As Reported | $1,514,859,000 | $61,366,000 | $620,525,000 | $579,440,000 |
| Net Income Common Stockholders | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Net Income | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Net Income Including Noncontrolling Interests | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Net Income Continuous Operations | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Pretax Income | $1,664,451,000 | $316,630,000 | $834,215,000 | $529,116,000 |
| Special Income Charges | $172,105,000 | $-40,003,000 | $-34,833,000 | $-12,149,000 |
| Interest Income Non Operating | $105,600,000 | $128,710,000 | $158,414,000 | $40,451,000 |
| Operating Income | $1,342,790,000 | $101,294,000 | $655,358,000 | $591,626,000 |
| Gross Profit | $4,769,142,000 | $3,929,117,000 | $3,440,659,000 | $3,187,635,000 |
| Per Share | ||||
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 |
| Basic EPS | $6.59 | $0.16 | $2.67 | $1.53 |
| Other | ||||
| Tax Effect Of Unusual Items | $43,905,205 | $15,964,620 | $2,569,770 | $-35,507,084 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,566,750,000 | $332,136,000 | $910,366,000 | $699,376,000 |
| Total Unusual Items | $193,415,000 | $76,022,000 | $9,060,000 | $-99,739,000 |
| Total Unusual Items Excluding Goodwill | $193,415,000 | $76,022,000 | $9,060,000 | $-99,739,000 |
| Reconciled Depreciation | $93,286,000 | $89,248,000 | $82,660,000 | $67,855,000 |
| EBITDA (Bullshit earnings) | $1,760,165,000 | $408,158,000 | $919,426,000 | $599,637,000 |
| EBIT | $1,666,879,000 | $318,910,000 | $836,766,000 | $531,782,000 |
| Diluted Average Shares | $200,700,000 | $210,530,000 | $225,928,000 | $223,958,000 |
| Basic Average Shares | $195,204,000 | $207,110,000 | $223,628,000 | $222,004,000 |
| Diluted NI Availto Com Stockholders | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Tax Provision | $377,801,000 | $284,015,000 | $236,616,000 | $188,456,000 |
| Other Special Charges | $-242,251,000 | - | - | - |
| Write Off | $76,275,000 | $0 | $5,631,000 | - |
| Restructuring And Mergern Acquisition | $-6,129,000 | $40,003,000 | $29,202,000 | $12,149,000 |
| Gain On Sale Of Security | $21,310,000 | $116,025,000 | $43,893,000 | $-87,590,000 |
| Research And Development | $2,050,152,000 | $2,606,848,000 | $1,627,594,000 | $1,585,936,000 |
| Selling General And Administration | $1,376,200,000 | $1,222,000,000 | $1,155,662,000 | $1,002,100,000 |
| Other Gand A | $860,900,000 | $769,900,000 | $775,100,000 | $659,800,000 |
| Salaries And Wages | $515,300,000 | $452,100,000 | $386,200,000 | $342,300,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,917,347,000 | $3,178,232,000 | $4,910,699,000 | $4,085,307,000 |
| Total Assets | $6,957,973,000 | $5,444,322,000 | $6,782,107,000 | $5,840,984,000 |
| Total Non Current Assets | $1,934,071,000 | $2,205,292,000 | $2,136,705,000 | $1,748,134,000 |
| Other Non Current Assets | $362,250,000 | $360,797,000 | $260,917,000 | $106,097,000 |
| Non Current Deferred Assets | $515,294,000 | $762,071,000 | $631,886,000 | $457,941,000 |
| Non Current Deferred Taxes Assets | $515,294,000 | $762,071,000 | $631,886,000 | $457,941,000 |
| Goodwill And Other Intangible Assets | $250,131,000 | $269,396,000 | $279,138,000 | $284,812,000 |
| Other Intangible Assets | $117,131,000 | $113,803,000 | $123,545,000 | $129,219,000 |
| Current Assets | $5,023,902,000 | $3,239,030,000 | $4,645,402,000 | $4,092,850,000 |
| Other Current Assets | $317,831,000 | $168,912,000 | $182,830,000 | $167,011,000 |
| Inventory | $101,060,000 | $58,872,000 | $62,972,000 | $41,995,000 |
| Receivables | $1,024,407,000 | $853,154,000 | $743,557,000 | $644,879,000 |
| Accounts Receivable | $1,024,407,000 | $853,154,000 | $743,557,000 | $644,879,000 |
| Cash Cash Equivalents And Short Term Investments | $3,580,604,000 | $2,158,092,000 | $3,656,043,000 | $3,238,965,000 |
| Cash And Cash Equivalents | $3,097,817,000 | $1,687,829,000 | $3,213,376,000 | $2,951,422,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $40,412,000 | $43,544,000 | $38,287,000 | $41,457,000 |
| Long Term Debt And Capital Lease Obligation | $30,199,000 | $33,542,000 | $29,162,000 | $30,083,000 |
| Current Debt And Capital Lease Obligation | $10,213,000 | $10,002,000 | $9,125,000 | $11,374,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,790,495,000 | $1,996,694,000 | $1,592,270,000 | $1,470,865,000 |
| Total Non Current Liabilities Net Minority Interest | $275,325,000 | $354,847,000 | $351,891,000 | $313,788,000 |
| Other Non Current Liabilities | $245,126,000 | $321,305,000 | $322,729,000 | $283,705,000 |
| Current Liabilities | $1,515,170,000 | $1,641,847,000 | $1,240,379,000 | $1,157,077,000 |
| Other Current Liabilities | $131,867,000 | $98,103,000 | $111,747,000 | $104,970,000 |
| Payables And Accrued Expenses | $502,551,000 | $907,012,000 | $686,245,000 | $709,839,000 |
| Payables | $214,693,000 | $221,246,000 | $151,896,000 | $284,654,000 |
| Total Tax Payable | $4,755,000 | $23,781,000 | $42,295,000 | $7,108,000 |
| Accounts Payable | $209,938,000 | $197,465,000 | $109,601,000 | $277,546,000 |
| Equity | ||||
| Common Stock Equity | $5,167,478,000 | $3,447,628,000 | $5,189,837,000 | $4,370,119,000 |
| Total Equity Gross Minority Interest | $5,167,478,000 | $3,447,628,000 | $5,189,837,000 | $4,370,119,000 |
| Stockholders Equity | $5,167,478,000 | $3,447,628,000 | $5,189,837,000 | $4,370,119,000 |
| Gains Losses Not Affecting Retained Earnings | $25,462,000 | $-13,121,000 | $13,106,000 | $15,069,000 |
| Other Equity Adjustments | $25,462,000 | $-13,121,000 | $13,106,000 | $15,069,000 |
| Retained Earnings | $213,769,000 | $-1,072,881,000 | $160,385,000 | $-437,214,000 |
| Long Term Equity Investment | $47,991,000 | $18,814,000 | $187,716,000 | $133,676,000 |
| Other | ||||
| Ordinary Shares Number | $198,460,009 | $193,434,305 | $224,286,862 | $222,746,719 |
| Share Issued | $198,460,009 | $193,434,305 | $224,286,862 | $222,746,719 |
| Tangible Book Value | $4,917,347,000 | $3,178,232,000 | $4,910,699,000 | $4,085,307,000 |
| Invested Capital | $5,167,478,000 | $3,447,628,000 | $5,189,837,000 | $4,370,119,000 |
| Working Capital | $3,508,732,000 | $1,597,183,000 | $3,405,023,000 | $2,935,773,000 |
| Capital Lease Obligations | $40,412,000 | $43,544,000 | $38,287,000 | $41,457,000 |
| Total Capitalization | $5,167,478,000 | $3,447,628,000 | $5,189,837,000 | $4,370,119,000 |
| Additional Paid In Capital | $4,928,049,000 | $4,533,437,000 | $5,016,122,000 | $4,792,041,000 |
| Capital Stock | $198,000 | $193,000 | $224,000 | $223,000 |
| Common Stock | $198,000 | $193,000 | $224,000 | $223,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $30,199,000 | $33,542,000 | $29,162,000 | $30,083,000 |
| Current Capital Lease Obligation | $10,213,000 | $10,002,000 | $9,125,000 | $11,374,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $228,071,000 | $188,677,000 | $153,348,000 | $138,761,000 |
| Current Provisions | $642,468,000 | $438,053,000 | $279,914,000 | $192,133,000 |
| Current Accrued Expenses | $287,858,000 | $685,766,000 | $534,349,000 | $425,185,000 |
| Investments And Advances | $47,991,000 | $18,814,000 | $187,716,000 | $133,676,000 |
| Goodwill | $133,000,000 | $155,593,000 | $155,593,000 | $155,593,000 |
| Net PPE | $758,405,000 | $794,214,000 | $777,048,000 | $765,608,000 |
| Accumulated Depreciation | $-375,066,000 | $-327,984,000 | $-269,934,000 | $-212,814,000 |
| Gross PPE | $1,133,471,000 | $1,122,198,000 | $1,046,982,000 | $978,422,000 |
| Construction In Progress | $30,485,000 | $46,062,000 | $13,544,000 | $47,224,000 |
| Other Properties | $305,119,000 | $282,830,000 | $266,765,000 | $241,750,000 |
| Machinery Furniture Equipment | $176,567,000 | $180,569,000 | $170,987,000 | $114,849,000 |
| Buildings And Improvements | $610,027,000 | $597,342,000 | $584,755,000 | $564,170,000 |
| Land And Improvements | $11,273,000 | $15,395,000 | $10,931,000 | $10,429,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $482,787,000 | $470,263,000 | $442,667,000 | $287,543,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,329,631,000 | $235,174,000 | $449,001,000 | $892,108,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,413,498,000 | $335,337,000 | $496,487,000 | $969,941,000 |
| Cash Flow From Continuing Operating Activities | $1,413,498,000 | $335,337,000 | $496,487,000 | $969,941,000 |
| Operating Gains Losses | $-21,310,000 | $-116,025,000 | $-43,893,000 | $87,590,000 |
| Investing Activities | ||||
| Capital Expenditure | $-83,867,000 | $-100,163,000 | $-47,486,000 | $-77,833,000 |
| Investing Cash Flow | $-102,610,000 | $157,517,000 | $-207,677,000 | $-78,542,000 |
| Cash Flow From Continuing Investing Activities | $-102,610,000 | $157,517,000 | $-207,677,000 | $-78,542,000 |
| Capital Expenditure Reported | $-58,867,000 | $-86,263,000 | $-32,486,000 | $-77,833,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-2,004,790,000 | $0 | $0 |
| Financing Cash Flow | $101,039,000 | $-2,021,547,000 | $-20,033,000 | $-794,000 |
| Cash Flow From Continuing Financing Activities | $101,039,000 | $-2,021,547,000 | $-20,033,000 | $-794,000 |
| Net Other Financing Charges | $-116,179,000 | $-62,260,000 | $-52,509,000 | $-59,047,000 |
| Net Common Stock Issuance | $0 | $-2,004,790,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-4,544,000 | $-3,798,000 | $-3,360,000 | $-2,862,000 |
| End Cash Position | $3,099,669,000 | $1,689,451,000 | $3,215,221,000 | $2,953,120,000 |
| Beginning Cash Position | $1,689,451,000 | $3,215,221,000 | $2,953,120,000 | $2,059,160,000 |
| Effect Of Exchange Rate Changes | $-1,709,000 | $2,923,000 | $-6,676,000 | $3,355,000 |
| Changes In Cash | $1,411,927,000 | $-1,528,693,000 | $268,777,000 | $890,605,000 |
| Proceeds From Stock Option Exercised | $221,762,000 | $49,301,000 | $35,836,000 | $61,115,000 |
| Common Stock Payments | $0 | $-2,004,790,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-4,544,000 | $-3,798,000 | $-3,360,000 | $-2,862,000 |
| Net Long Term Debt Issuance | $-4,544,000 | $-3,798,000 | $-3,360,000 | $-2,862,000 |
| Long Term Debt Payments | $-4,544,000 | $-3,798,000 | $-3,360,000 | $-2,862,000 |
| Net Investment Purchase And Sale | $-18,743,000 | $257,680,000 | $-160,191,000 | $-709,000 |
| Sale Of Investment | $284,639,000 | $516,050,000 | $305,829,000 | $79,151,000 |
| Purchase Of Investment | $-303,382,000 | $-258,370,000 | $-466,020,000 | $-79,860,000 |
| Net Intangibles Purchase And Sale | $-25,000,000 | $-13,900,000 | $-15,000,000 | $0 |
| Purchase Of Intangibles | $-25,000,000 | $-13,900,000 | $-15,000,000 | $0 |
| Change In Working Capital | $-527,162,000 | $138,244,000 | $-248,651,000 | $198,810,000 |
| Change In Payables And Accrued Expense | $-141,640,000 | $367,098,000 | $62,669,000 | $325,632,000 |
| Change In Accrued Expense | $-148,202,000 | $278,939,000 | $230,614,000 | $220,196,000 |
| Change In Payable | $6,562,000 | $88,159,000 | $-167,945,000 | $105,436,000 |
| Change In Account Payable | $6,562,000 | $88,159,000 | $-167,945,000 | $105,436,000 |
| Change In Prepaid Assets | $-156,237,000 | $10,365,000 | $-42,491,000 | $-30,739,000 |
| Change In Inventory | $-58,513,000 | $-127,633,000 | $-170,151,000 | $-67,504,000 |
| Change In Receivables | $-170,772,000 | $-111,586,000 | $-98,678,000 | $-28,579,000 |
| Changes In Account Receivables | $-170,772,000 | $-111,586,000 | $-98,678,000 | $-28,579,000 |
| Other Non Cash Items | $8,728,000 | $10,750,000 | $46,150,000 | $29,515,000 |
| Stock Based Compensation | $249,346,000 | $266,058,000 | $215,889,000 | $188,420,000 |
| Asset Impairment Charge | $76,275,000 | $0 | $5,631,000 | - |
| Deferred Tax | $247,685,000 | $-85,553,000 | $-158,898,000 | $57,091,000 |
| Deferred Income Tax | $247,685,000 | $-85,553,000 | $-158,898,000 | $57,091,000 |
| Depreciation Amortization Depletion | $93,286,000 | $89,248,000 | $82,660,000 | $67,855,000 |
| Depreciation And Amortization | $93,286,000 | $89,248,000 | $82,660,000 | $67,855,000 |
| Gain Loss On Investment Securities | $-21,310,000 | $-116,025,000 | $-43,893,000 | $87,590,000 |
| Net Income From Continuing Operations | $1,286,650,000 | $32,615,000 | $597,599,000 | $340,660,000 |
| Income Tax Paid Supplemental Data | - | $373,056,000 | $378,206,000 | $136,242,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $-43,893,000 | $87,590,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $17,366,000 |
| Interest Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-23